<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159701">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01824394</url>
  </required_header>
  <id_info>
    <org_study_id>reMARQable</org_study_id>
    <nct_id>NCT01824394</nct_id>
  </id_info>
  <brief_title>nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>reMARQable nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate safety and effectiveness of nMARQ Catheter System [nMARQ] compared with
      THERMOCOOL® Navigational Family of catheters in treating subjects with drug-refractory
      symptomatic paroxysmal atrial fibrillation (PAF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Early-onset primary adverse events</measure>
    <time_frame>7 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of early-onset primary adverse events within 7 days of the atrial fibrillation ablation procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of arrhythmia</measure>
    <time_frame>3-12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Freedom from documented, symptomatic atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) episodes based on electrocardiographic data through the effectiveness evaluation period (3-12 months follow-up post ablation procedure) in the intention to treat (ITT) population as randomized.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>nMARQ Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nMARQ Catheter System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaviStar ThermoCool Catheters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>THERMOCOOL®  Navigational family of catheters</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nMARQ Navigation Catheters</intervention_name>
    <arm_group_label>nMARQ Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NaviStar ThermoCool Catheters</intervention_name>
    <arm_group_label>NaviStar ThermoCool Catheters</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with symptomatic paroxysmal AF who have had at least one AF episode
             documented within one (1) year prior to enrollment. Documentation may include ECG,
             transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip.

          2. Patients who have failed at least one antiarrhythmic drug (AAD; class I or III, or
             atrioventricular (AV) nodal blocking agents such as beta blockers and calcium channel
             blockers) as evidenced by recurrent symptomatic AF, or intolerance to the AAD.

          3. Age 18 years or older.

          4. Signed Patient Informed Consent Form (ICF).

          5. Able and willing to comply with all pre-, post-, and follow-up testing and
             requirements.

        Exclusion Criteria:

          1. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac
             cause.

          2. Previous ablation for atrial fibrillation.

          3. Patients on amiodarone at any time during the past 3 months prior to enrollment.

          4. AF episodes lasting &gt; 7 days.

          5. Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical
             procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and
             presence of a prosthetic valve).

          6. Coronary artery bypass graft (CABG) procedure within the last 180 days (6 months).

          7. Awaiting cardiac transplantation or other cardiac surgery within the next 365 days
             (12 months).

          8. Documented left atrial thrombus on imaging.

          9. History of a documented thromboembolic event within the past one (1) year.

         10. Diagnosed atrial myxoma.

         11. Presence of implanted cardioverter defibrillator (ICD).

         12. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or
             chronic obstructive pulmonary disease) or any other disease or malfunction of the
             lungs or respiratory system that produces chronic symptoms.

         13. Significant congenital anomaly or medical problem that in the opinion of the
             investigator would preclude enrollment in this study.

         14. Women who are pregnant (as evidenced by pregnancy test if subject is of child-bearing
             age and potential) or breast feeding.

         15. Acute illness or active systemic infection or sepsis.

         16. Unstable angina.

         17. Myocardial infarction within the previous 60 days (2 months).

         18. Left ventricular ejection fraction &lt;40%.

         19. History of blood clotting or bleeding abnormalities.

         20. Contraindication to anticoagulation (i.e., heparin, dabigatran, Vitamin K Antagonists
             such as warfarin).

         21. Life expectancy less than 365 days (12 months).

         22. Enrollment in an investigational study evaluating another device or drug.

         23. Uncontrolled heart failure or NYHA Class III or IV heart failure.

         24. Presence of intramural thrombus, tumor or other abnormality that precludes catheter
             introduction or manipulation.

         25. Presence of a condition that precludes vascular access.

         26. Left atrial size &gt;50 mm.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josh Der</last_name>
    <phone>(909) 839-8843</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Gunter</last_name>
      <phone>205-975-4338</phone>
    </contact>
    <investigator>
      <last_name>Tom McElderry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Park</last_name>
      <phone>213-977-4175</phone>
    </contact>
    <investigator>
      <last_name>Anil Bhandari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leann Goodwin</last_name>
      <phone>407-303-8059</phone>
    </contact>
    <investigator>
      <last_name>George Monir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Murrieta</last_name>
      <phone>404-605-3074</phone>
    </contact>
    <investigator>
      <last_name>Andrew Wickliffe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Del Priore</last_name>
      <phone>708-216-2644</phone>
    </contact>
    <investigator>
      <last_name>David Wilber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jaeger</last_name>
      <phone>913-588-9627</phone>
    </contact>
    <investigator>
      <last_name>Dhanunjaya Lakkireddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Muir</last_name>
      <phone>859-260-6429</phone>
    </contact>
    <investigator>
      <last_name>Gery Tomassoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai Doan</last_name>
      <phone>617-726-0280</phone>
    </contact>
    <investigator>
      <last_name>Moussa Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Pellegrini</last_name>
      <phone>617-732-5241</phone>
    </contact>
    <investigator>
      <last_name>Gregory Michaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Kerwin</last_name>
      <phone>612-863-8200</phone>
    </contact>
    <investigator>
      <last_name>Daniel Melby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Brunetti</last_name>
      <phone>973-971-5951</phone>
    </contact>
    <investigator>
      <last_name>Jonathan S Sussman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Kearney</last_name>
      <phone>201-447-8045</phone>
    </contact>
    <investigator>
      <last_name>Jonathan S Steinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine, The</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Kuznekoff</last_name>
      <phone>212-263-7704</phone>
    </contact>
    <investigator>
      <last_name>Larry Chinitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Hickey</last_name>
      <phone>919-668-3524</phone>
    </contact>
    <investigator>
      <last_name>James P. Daubert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Schaffer</last_name>
      <phone>216-445-6917</phone>
    </contact>
    <investigator>
      <last_name>Bruce Lindsay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center, The</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keri Baia</last_name>
      <phone>614-685-4621</phone>
    </contact>
    <investigator>
      <last_name>Emile Daoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Killian</last_name>
      <phone>215-615-5299</phone>
    </contact>
    <investigator>
      <last_name>David Frankel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research - St. David's</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Cardinal</last_name>
      <phone>512-458-9410</phone>
    </contact>
    <investigator>
      <last_name>Rodney Horton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunigal Khanum</last_name>
      <phone>469-814-4732</phone>
    </contact>
    <investigator>
      <last_name>J. Brian DeVille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Hall</last_name>
      <phone>804-828-4700</phone>
    </contact>
    <investigator>
      <last_name>Kenneth Ellenbogen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libor Machálek</last_name>
      <phone>00420 257273301</phone>
    </contact>
    <investigator>
      <last_name>Petr Neuzil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale &quot;F. Miulli&quot;</name>
      <address>
        <city>Acquaviva Delle Fonti</city>
        <state>Strada</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Petruzzi</last_name>
      <phone>+39 32 06 975 496</phone>
    </contact>
    <investigator>
      <last_name>Massimo Grimaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Czech Republic</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nMARQ</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Drug Refractory</keyword>
  <keyword>Radio Frequency</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
